Clave A, et al. - In this randomized, double-blind, placebo-controlled trial, researchers assessed the effectiveness of tranexamic acid (TXA) combined with rivaroxaban thromboprophylaxis to reduce blood loss after primary cementless total hip arthroplasty (THA). They observed a significant decline in perioperative real blood loss (RBL) when TXA was given in comparison with placebo with mean differences, 525.3 ml (short-TXA vs placebo) and 550.1 ml (long-TXA vs placebo). They recorded no venous or arterial thromboembolic complications. They sustained the non-inferiority of a short- vs a long-TXA protocol in overcoming perioperative RBL in secondary analysis.